SCHEMBL6897260

SCHEMBL6897260

C[C@H](NC(=O)N(CCO)CCC1CC1)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.35
LTA4H P09960 1/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
LPAR1 Q92633 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
CASR P41180 1/20 0.32
MME P08473 2/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA9 Q16790 1/20 0.31
KDM5A P29375 1/20 0.31
KDM7A Q6ZMT4 1/20 0.31
KDM4C Q9H3R0 1/20 0.31
PHF8 Q9UPP1 1/20 0.31
KDM2A Q9Y2K7 1/20 0.31
RAB9A P51151 1/20 0.30
ACE P12821 1/20 0.30
CPA1 P15085 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6896598 0.96 LTA4H (0.39) MCHR1LTA4HTP53POLBSMN1; SMN2
SCHEMBL6896957 0.94 LTA4H (0.40) MCHR1LTA4HPOLBSMN1; SMN2LPAR1
SCHEMBL6897170 0.93 LTA4H (0.42) MCHR1LTA4HTP53POLBHRH3
SCHEMBL6897064 0.93 LTA4H (0.42) MCHR1LTA4HTP53POLBHRH3
SCHEMBL6894998 0.93 LTA4H (0.42) MCHR1LTA4HTP53POLBHRH3
SCHEMBL6897605 0.85 LTA4H (0.41) MCHR1LTA4HTP53POLBLPAR1
SCHEMBL6891022 0.82 MCHR1 (0.33) MCHR1LTA4HTP53POLBSMN1; SMN2
SCHEMBL27538287 0.82 MCHR1 (0.33) MCHR1LTA4HTP53POLBSMN1; SMN2
SCHEMBL27560038 0.82 KMT2A (0.37) MCHR1HRH3CA12KMT2A
SCHEMBL6898559 0.79 MCHR1 (0.32) MCHR1LPAR1HRH3CASRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH MCHR1 1236/4885LTA4H 411/4885TP53 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.